In our study, a univariate analysis showed that specific characteristics (female, non-smoking, PS 0–1, adenocarcinoma, recurrent disease, EGFR mutations, receiving EGFR-TKI therapy) predicted a better survival outcome. Here, EGFR is linked to adenocarcinoma.